Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Instant Alerts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
Biotechnology
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus on Core Business
Codexis Inc (CDXS) reports a significant increase in product revenue and outlines a clear path to profitability by 2026, despite challenges in R&D revenue and net loss reduction. Nov 01, 2024
Biotechnology
BioInvent International AB (STU:BIX) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with Strategic Partnerships
Despite a decline in net sales and increased operating costs, BioInvent International AB (STU:BIX) strengthens its position with promising clinical developments and robust cash reserves. Nov 01, 2024
Biotechnology
Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions
Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite challenges in product sales growth. Nov 01, 2024